Dr. Nebu Koshy

Oncology | Hematology
3410 Worth Street, Suite 300, 
Dallas, TX 
Offers Telehealth
24 Years of Experience
3410 Worth Street, Suite 300, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nebu Koshy is a Hematologist and an Oncologist in Dallas, Texas. Dr. Koshy has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Jawaharlal Nehru Medical College, 2002.0
Residency
Internal Medicine, Louisiana State University In Shreveport
Specialties
Oncology
Hematology
Licenses
Internal Medicine in LA
Fellowships
Hematology/Oncology, Louisiana State University In Shreveport
Hematology/Oncology, LA State Univ at Shreveport School of Medicine
Bone Marrow/Stem Cell Transplant, Weill Medical College of Cornell University
Bone Marrow and Stem Cell Transplant, Weill Cornell Medicine
Hospital Affiliations
Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 300, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

16 Total Publications

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 19, 2024
Similar Doctors
Advanced in Gitelman Syndrome
Dr. Vikas Bhushan
Hematology Oncology | Oncology | Hematology
Advanced in Gitelman Syndrome
Dr. Vikas Bhushan
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

4700 N Galloway Ave, 
Mesquite, TX 
 (9.2 miles away)
972-566-5400
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Vikas Bhushan is a Hematologist Oncology specialist and an Oncologist in Mesquite, Texas. Dr. Bhushan is rated as a Distinguished provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhushan is currently accepting new patients.

Advanced in Gitelman Syndrome
Dr. Rohan Gupta
Hematology Oncology | Hematology | Oncology
Advanced in Gitelman Syndrome
Dr. Rohan Gupta
Hematology Oncology | Hematology | Oncology

Oncology-Hematology Consultants PA

920 Santa Fe Dr, 
Weatherford, TX 
 (58.5 miles away)
817-596-0637
Languages Spoken:
English, Hindi, Mandarin, Spanish, Taiwanese, Telugu, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohan Gupta is a Hematologist Oncology specialist and a Hematologist in Weatherford, Texas. Dr. Gupta is rated as an Advanced provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Thrombocytopenia, Anemia, Chronic Familial Neutropenia, Agranulocytosis, and Bone Marrow Aspiration. Dr. Gupta is currently accepting new patients.

Experienced in Gitelman Syndrome
Dr. Talha Riaz
Hematology Oncology | Hematology | Oncology
Experienced in Gitelman Syndrome
Dr. Talha Riaz
Hematology Oncology | Hematology | Oncology

Oncology-Hematology Consultants PA

800 W Magnolia Ave, 
Fort Worth, TX 
 (32.4 miles away)
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Talha Riaz is a Hematologist Oncology specialist and a Hematologist in Fort Worth, Texas. Dr. Riaz is rated as an Advanced provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Breast Cancer, and Intraductal Papilloma. Dr. Riaz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koshy's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile